Amy Feldman is a Forbes senior editor, covering healthcare, based in New York. She’s written features on OpenAI’s healthcare plans, Chai Discovery, Jennifer Doudna’s $1 billion plan for gene-editing, Apnimed’s sleep apnea pill, Fred Moll’s surgical robotics investments, OpenEvide
The Startup Behind The Pill For Sleep Apnea Raises $192 Million In IPO
Apnimed got a new CEO in anticipation of its public offering. Its pill for sleep apnea could receive approval early next year.
The Startup Using AI To Make Hearing Aids Better
In this week’s edition of InnovationRx, we look at Fortell’s efforts to make a better hearing aid, Abby Care’s business getting payment for caregivers, J&J’s $5.5 billion talc settlement, Scribe Therapeutics’ IPO, and more.
The Potential Havoc Of Generic Drug Tariffs
In this week’s edition of InnovationRx, we look at the companies looking to cash in on the coming peptide bonanza, the ongoing cyclosporiasis outbreak, Tempus’s acquisition of a cancer-testing company, and more.
Peptides May Soon Be Legal. These Companies Are Ready To Cash In
With an FDA panel expected to recommend legal production of as many as seven peptides this week, compounding pharmacies and telehealth companies are preparing for the coming bonanza.
Founder Of $1 Billion Cancer Care Startup Steps Down As CEO
In this week’s edition of InnovationRx, Thyme Care gets new leadership, the intestinal illness spreads, Chai Discovery confirms its $400 million raise, and more.
Boom Times For Autoimmune Disease Therapies
In this week’s edition of InnovationRx, we look at the boom in autoimmune disease therapies, OpenAI’s healthcare push, Vertex’s $10 billion purchase of Crinetics, and more.
How OpenAI Plans To Win Over Doctors, Patients And Hospitals
The AI juggernaut is all-in on the healthcare industry, launching three new products in the last six months. But it needs to make sure ChatGPT is accurate enough for the millions of people who already use it for health advice.
Why Axsome Stock Has Doubled In Nine Months
In this week’s edition of InnovationRx, we look at Axsome’s growing pipeline, HistoSonics innovative cancer treatment, state litigation over Medicaid work requirements, and more.
AbbVie’s $11 Billion Immunology Bet
In this week’s edition of InnovationRx, we look at AbbVie’s new megadeal, an agentic AI startup saving Medicare $2 million a week, how new student loan rules could degrade healthcare and more.
These 29-Year-Olds’ AI Agent For Scheduling Doctor Visits Is Now Worth $1.2 Billion
Scheduling doctor appointments is its own form of hell for both physicians and patients. Assort Health’s AI fix helped it raise its third venture round in 14 months.